Study of GS-3242 in Participants With HIV-1 This study aims to learn more about a new medicine called GS-3242 for people who have HIV-1, a virus that affects the immune system. The study is part of a larger research project to understand how new medicines can help control the virus. Participants must have certain levels of the virus and immune cells to join. They should not have taken any antiretroviral (ARV) medications recently, which are drugs used to treat HIV. The study is only for people who are willing to follow specific meal rules on days they take the medicine. Key Points:

• Participants will start a new treatment on Day 11 and continue as per the study plan.
• Participants must be willing to follow meal guidelines on days they take the study medicine.
• The study excludes people with certain health conditions or those taking specific medications.

Participants should not have serious liver problems or other infections like Hepatitis B or C. Women who are pregnant or breastfeeding cannot join. This study helps researchers learn more about better HIV treatments.